

Practical Insights in Novel Immune Therapies in Multiple Myeloma

OCTOBER 6, 2022 | VIENNA, AUSTRIA | LINDER HOTEL AM BELVEDERE

DRAFT PROGRAM AGENDA

1:30-1:35 PM	Welcome Nikhil Munshi/Hermann Einsele
1:35-1:45 PM	Defining the unmet need in relapsed/refractory multiple myeloma Monika Engelhardt
1:45-1:55 PM	Targeting BCMA with CAR T cell therapy and clinical results Marc Raab
1:55-2:05 PM	Targeting BCMA with TCES Ralph Wäsch
2:05-2:15 PM	Blood biopsy - based approaches for the monitoring of novel immunotherapy Johannes Waldschmidt
2:15-2:30 PM	Panel Discussion Moderators: Nikhil Munshi / Wolfgang Willenbacher
2:30-2:40 PM	Patients and the process – defining patient selection for TCEs/CAR T cell therapy in practice - Understanding of CAR T eligibility to ensure the right patient is referred for CAR T therapy Katja Weisel
2:40-2:50 PM	Infections and prevention of infections in patients on BiTEs and CAR T cells Heinz Ludwig
2:50-3:00 PM	Managing TCE/CAR T cell toxicities: Practical tips for short and long-term adverse events associated with CAR T cell therapy (focus on needs for coordination between community centers and CAR T centers) Florian Bassermann
3:00-3:10 PM	Case study: Impact of Immunometabolic Host Conditions on Outcomes and Toxicity of CART-T Cell Therapy Sebastian Theurich
3:10-3:25 PM	Panel Discussion Moderators: Noopur Raje / Ulrich Keller / Hartmut Goldschmidt
3:25-3:35 PM	Interaction between the Immune System and Multiple Myeloma Christoph Driessen
3:35-3:45 PM	Novel CAR constructs and concepts in myeloma Michael Hudecek
3:45-3:55 PM	Mechanisms of resistance to T cell engaging therapies Niels Weinhold
3:55-4:05 PM	Future advances in immune therapies and cellular therapy Hermann Einsele
4:05-4:15 PM	Case study Jan Krönke
4:15-4:30 PM	Panel Discussion Moderators: Martin Gramatzki / Ulrich Jäger

TO REGISTER: <https://www.eventcreate.com/e/imsedseries>
Registration is complimentary.

The International Myeloma Society gratefully acknowledges the following organizations for their support of the workshop:



Supported by a grant from Pfizer Inc.